Portfolio
Innovative Oncology therapies across multiple drug classes to improve patient lives
Small Molecule
Candidate Name
Class
Indication
EP0042 is an orally available dual inhibitor of FLT3 & Aurora kinases A and B. It is currently being investigated in an adaptive phase 1/2 dose ranging and optimisation study in patients with relapsed / refractory acute myeloid leukaemia. Initial data from the ongoing study was presented at the 64th American Society of Hematology Annual Meeting in December 2022 and showed a favourable safety profile with preliminary signs of efficacy. EP0042 received Orphan Drug Designation from the U.S. FDA in February 2023.
Candidate Name
Class
Indication
EP0062 is an orally available non-steroidal SARM currently being investigated in an adaptive phase 1/2 dose optimisation study in patients with advanced ER+/AR+ breast cancer. Data from an initial phase 1 trial showed encouraging responses with an acceptable safety and tolerability profile in heavily pre-treated AR+/ER+/HER2- advanced breast cancer patients.
Candidate Name
Class
Indication
Candidate name
EP0031
Class
Selective RET Inhibitor
Point mutations or fusions in solid tumours that lead to activation of the RET kinase
Indication
RET+ Solid Tumours
Phase 1
EP0031 is a next generation selective RET inhibitor currently being investigated in a modular interventional phase 1/2 study in adult patients with advanced RET-altered malignancies.
Candidate Name
Class
Indication
Candidate name
Undisclosed
Class
Selective USP Inhibitor
Ubiquitin-specific proteases are involved in the regulation of multiple known cancer-related pathways. Specific inhibition of USP target proteins has the potential synergy of immune modulation and restoring p53 function in the treatment of cancer
Indication
All solid tumours
Pre-clinical
An orally available selective and potent inhibitor of a specific Ubiquitin Specific Protease with a unique multi-faceted mechanism of action.
Nanoparticle
Candidate Name
Class
Indication
Phase 2
Novel nanoparticle drug conjugate currently being investigated in an adaptive Phase 2a/b study in patients with advanced ovarian cancer in combination with olaparib.
